Day 1 :
Time : 10:00-10:45
He is currently working as deputy director for Institute of Regenerative Medicine and Biotherapy (IRMB) composed of a 150 persons. He is also a leader of a INSERM research team and director of a stem cell facility CHU (SAFE-iPSC) comprising more than 33 persons. He is mentoring 8 senior scientists (CR1, MCU, MCU/PH), 11 Ph.D. students and 3 Post-Docs, 9 technicians and engineers. Also he is an invited speaker in 48 national and international conferences and seminars in France and abroad in the last 5 years (3 plenary lectures).
Celgene Corporation, USA
Time : 10:45-11:30
Stefan Glück, MD, PhD is a medical oncologist with focus on solid tumors including brain cancer activities worldwide. Additionally, he is responsible for immuno-oncology programs in solid tumors and hematologic diseases and is in the area of early assets. He completed his medical studies at the University of West Berlin, Germany in 1978 followed by a medical oncology & bone marrow transplant fellowship in Toronto, Canada. Before becoming V.P. of Global Medical Affairs at Celgene Corp., he previously served as Sylvester Professor of Medicine at the Miller School of Medicine in Miami, Florida until 2014. From 2009-2010 he was assistant director of the Sylvester Comprehensive Cancer Center & associate chief for the Division of Hematology & Medical Oncology and from 2003-2008, he served as clinical director of the Braman Family Breast Cancer Institute in Miami, Florida. He has authored and co-authored over 260 articles and has written more than 350 papers at national and international meetings.
The idea of using the immune system to fight cancer is over 100 years old. (Paul Ehrlich’s “Magic Bullet”) But immunotherapy in solid tumors (ST) has been disappointing over the last several decades. A new molecular approach led to a better understanding of the immune system. Check point regulation, understanding roles of Tregs, Th1 and Th2, development of CAR-T cells, as well as regulation of DC and Macrophages, has led to discovery of immune checkpoint inhibitors (ICI) and modulators that are currently used in studies of several STs. Positive studies have led to the US FDA approval of a few of these compounds. Moreover, MSI high (and dMMR) are the currently “best” predictive markers for IO therapy and recently, Pembrolizumab was approved in ST with this companion diagnostic marker. A number of large clinical trials in many ST and in all phases are underway (over 1000). We will discuss the mechanism of action, its impact on solid tumors, and some of the early results and next generations ICI.